On February 13, 2023 (the "Petition Date"), Sorrento Therapeutics, Inc., and one (1) affiliated debtor (collectively, the "Debtors") filed voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code. The Debtors' bankruptcy cases are jointly administered under Case No. 23-90085 before the Honorable Christopher M. Lopez in the United States Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court"). 

Please note the Notice of Entry of Corrected Order Granting the Liquidating Trust's (1) to Establish Procedures to Resolve Litigation Regarding Avoidable Transfers of Scilex Stock Distributed to the Debtors’ Shareholders and (2) to Extend Trading Restriction to Implement Settlement (the “Corrected Order”) was filed at Docket No. 2505. The deadline to accept the Liquidating Trust's Offer has been extended to December 13, 2024 pursuant to the Corrected Order. Please click HERE to view the Notice.

Further, please take note that the Liquidation Trustee filed the Emergency Motion of the Liquidation Trustee of Sorrento Therapeutics, Inc. to Extend the Trading Restrictions on Sorrento’s Common Stock at Docket No. 2558. To view the document, please click HERE.  The Committee proposed Sorrento common stock trading restrictions through September 25, 2025. The Emergency Hearing will take place no later than on March 25, 2025.

Additional information about the bankruptcy cases may be obtained by calling the case information line at 833.278.6637 (toll-free) or 949.471.0454 (international). You may also submit an inquiry via email by clicking HERE.